TMPRSS2-ERG Fusion Prostate Cancer Prevalence Linked To PSA Density And Histologic Features In Multicenter US Prostate Biopsy Cohort

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology;  Cancer / Oncology
Article Date: 01 Jul 2008 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


ORLANDO, FL (UroToday.com) - In a certain proportion of prostate cancers, the prostate-specific androgen-regulated gene TMPRSS2 is fused with the gene for the transcription factor ERG. This gene fusion product may have prognostic significance in men with the CaP; however, the exact prevalence of the genetic abnormality is debated. For instance presence of the TMPRSS2-ERG gene fusion product was reported to be 36-54% in prostatectomy series, but was seen in only 15% of patients who participated in the Swedish watchful-waiting trial.

Mosquera and colleagues report the first study evaluating presence of TMPRSS2-ERG fusion in a cohort of men undergoing prostate biopsy. The authors, in a prospective fashion, assessed presence of this gene fusion in prostate needle biopsy specimens of 134 men from one of 5 clinical sites in Michigan or Massachusetts. Representative slides from each biopsy specimen were assessed for TMPRSS2-ERG status by FISH. Prevalence of the fusion product in CaP biopsy cores was 46% -- a fraction very similar to that seen in prostatectomy specimens reported by other groups. Also, as previously reported, none of the benign cores demonstrated the abnormality.

Ian Thompson, MD - the moderator of this podium session -- suggested that the investigators now test prostatectomy specimens of men in this study for TMPRSS2-ERG status.

Presented by Juan Miguel Mosquera, MD, et al., at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Contributing Editor Alexander Kutikov, MD

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

Article adapted by Medical News Today from original press release.
Visit our prostate / prostate cancer section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Urotoday. "TMPRSS2-ERG Fusion Prostate Cancer Prevalence Linked To PSA Density And Histologic Features In Multicenter US Prostate Biopsy Cohort." Medical News Today. MediLexicon, Intl., 1 Jul. 2008. Web.
11 Feb. 2012. <http://www.medicalnewstoday.com/releases/113376.php>

APA
Urotoday. (2008, July 1). "TMPRSS2-ERG Fusion Prostate Cancer Prevalence Linked To PSA Density And Histologic Features In Multicenter US Prostate Biopsy Cohort." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/113376.php.

Please note: If no author information is provided, the source is cited instead.


Prostate / Prostate Cancer

Most Popular Articles



Follow Our Prostate News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Prostate / Prostate Cancer Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »